In May 2006, GlycoFi Inc was acquired by Merck & Company Inc.. and until the Spring 2016 had operated as a wholly owned subsidiary of Merck. Following Merck's decision to close down the Lebanon NH operation of GlycoFi, - though contining use of the GlycoFi technologya method of making proteins from yeast. - one of the original founders stepped in and moved part of the remaining operations to Boston, MA. GlycoFi, Inc. had been focused on developing bio-therapeutics based on the glycan optimization technology. Based on a library of yeast strains that are engineered to perform specific human glycosylation at high fidelity, the developing technology was designed to address the biopharmaceutical industrys need for a safer, faster and more cost-effective therapeutic protein production. Therapeutic protein production had been operating at capacity and was being outpaced by the explosive growth in biopharmaceutical drug discovery. The intent of the founders was that their technology platform would alleviate that manufacturing bottleneck by engineering fungal expression systems that produce therapeutic proteins with human-like glycosylation structures
